While public statements do not instantly change federal law, this potential regulatory shift has sparked widespread excitement about the future of physician-led peptide therapies
[11] Clinical studies such as the SUSTAIN programme (semaglutide) and AWARD trials (dulaglutide) demonstrate that GLP-1 receptor agonists can reduce HbA1c by approximately 0.81.5% on average, with some patients achieving greater reductions depending on baseline values and adherence
Where payers and employers are looking From the payer perspective, GLP-1s are both promising and risky
Dramatically different experience
Poor sleep can increase cortisol levels and exacerbate inflammation, while quality deep sleep has been shown to reduce anxiety levels after just one night
The principles of sterile technique, gentle rehydration, and proper storage apply universally